Eli Lilly Mounjaro Clinical Trials

Weight Loss Drug Demand Drives Eli Lilly Sales

Hosted on MSN · 1d

Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Business Insider · 1d

Eli Lilly (NYSE:LLY) Speeds Up Weight Loss Drug Data Release

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s leader can become

The Financial Times · 1d

Eli Lilly expects to beat profit forecasts on obesity drug demand

The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to sharp sell-offs in its shares.

FierceBiotech1d

Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

13d

Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

FiercePharma1d

Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Yahoo Finance13d

Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli ... Lilly isn't stopping its ambitions in oncology care with just one treatment. Right now, the company has seven ...

BioSpace21h

After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

1don MSN

Eli Lilly reports mixed earnings, increases 2025 guidance

Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street ...

FierceBiotech1d

UPDATED: Eli Lilly lops Alzheimer's and obesity assets from pipeline in Q4 update

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

The Pharma Letter1d

Lilly reports better than expected earnings

US pharma major Eli Lilly today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial ...

1don MSN

Bernstein reiterates Eli Lilly stock Outperform with $1,100 target

Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results